Sharespot RSS feed | AIDS Education and Training Centers National Coordinating Resource Center (AETC NCRC)

HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA

Topic:

Publish Date:

Tuesday, September 27, 2016

We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART very early; patients were followed for 144 weeks. They found that DNA integration occurs early and rapidly, and that with early and continued ART, total and integrated HIV DNA drops quickly and continues to decrease over time.

Addiction Recovery and HIV: Finding Synergy

Topic:

Step 1: Preventing New Infections

Substance Use / Abuse

Case Finding

Syringe Service Programs (Needle Exchange)

Publish Date:

Friday, October 7, 2016

When we talk about HIV and drug addiction, we most often focus on injection drug use (IDU) as a risk factor for HIV transmission.

HIV and Heart Disease – NIH Explores the Connection

Topic:

Comorbidities, Coinfections, & Complications

Publish Date:

Wednesday, June 15, 2016

HIV-positive men and women can now live longer than ever before. A 2013 study found that a newly diagnosed 20-year-old on effective antiretroviral therapy (ART) can expect to live into their 70s, a lifespan only slightly lower than in people without HIV.^[1] While this is great news, physicians are learning that chronic HIV infection can place their patients at a higher risk of developing certain health problems earlier in life. One example is heart disease.

PrEP: Bone Density Improves after Stopping TDF/FTC

Topic:

Pre-exposure Prophylaxis

Publish Date:

Wednesday, May 4, 2016

Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD) both in HIV-infected patients treated with TDF-containing ARV regimens and in HIV-uninfected persons who use it for PrEP.

Use of Dolutegravir in Dialysis

Topic:

Comorbidities, Coinfections, & Complications

Publish Date:

Wednesday, May 4, 2016

Dolutegravir has several characteristics that, in theory, suggest it will not be significantly removed by dialysis:

Accessibility: The Bigger Picture

Topic:

Training Program Management

Publish Date:

Thursday, June 2, 2016

selection from infographic. 74.8 million adults in the U.S. have at least one disibility or mobility limitation. I have been working on website accessibility for many years in my role as Production Manager at the UCSF Center for HIV Information. Despite that experience, I still encounter problems that confound me. I recently reached out to an accessibility expert for ideas on how to manage a particularly difficult compliance problem.

Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

Topic:

Antiretroviral Therapy

Drug Interactions

Pharmacologic Topics

Step 5: Effective Drug Treatment of HIV

Reproductive Health

Publish Date:

Tuesday, April 12, 2016

Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir during pregnancy.

Switching from TDF/FTC to TAF/FTC

Topic:

Step 5: Effective Drug Treatment of HIV

Antiretroviral Therapy

Managing Adverse Effects

Pharmacologic Topics

Publish Date:

Friday, March 18, 2016

Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with boosted PIs, 200/25 mg without boosters) or continued on TDF/FTC; the background third agents were not changed. At 48 weeks, 94.3% of TAF/FTC recipients and 93% of TDF/FTC recipients maintained HIV RNA suppression; the difference was not significant.

Tissue Levels of TAF: Too Low for PrEP?

Topic:

Antiretroviral Therapy

Pharmacologic Topics

Pre-exposure Prophylaxis

Publish Date:

Thursday, March 17, 2016

A pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue and in anogenital fluid samples after administration of oral tenofovir alafenamide (TAF). This is of interest because administration of TAF (25 mg orally) results in 90% lower plasma concentrations of the TFV and TFV-DP than TDF, and 7-fold higher levels of TFV in mononuclear cells.

Tips for Successful Linkage to Care

Topic:

Step 3: Connecting HIV-Infected People to Quality HIV Care

Publish Date:

Thursday, February 4, 2016

I would like to start this new year introducing myself to the AIDS Education and Training Center (AETC) community. I had the pleasure of joining the AETC National Coordinating Resource Center (NCRC) as a Health Educator in December 2015. I look forward to using my skill set as a Certified Health Educator Specialist and seasoned patient navigator/linkage to care coordinator (LTCC) to provide a perspective based on direct interaction and delivery of care to clients from another standpoint in the healthcare team.

Pages